Higher plasma concentrations of tyrosine kinase inhibitors (TKI), such as pazopanib, are associated with improved clinical outcomes. However, TKI pharmacokinetics exhibit significant interpatient variability, resulting in inconsistent and unpredictable plasma drug levels. An individualized dosing approach based on patient pharmacokinetics data and toxicity can potentially optimize plasma concentrations of pazopanib. Clin Cancer Res; 22(23); 5626–8. ©2016 AACR.
See related article by Verheijen et al., p. 5738
from Cancer via ola Kala on Inoreader http://ift.tt/2fTN6mm
via IFTTT
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου